@entity1665 associated with XXXX therapy.

@entity1665 @entity1 @entity19406 @entity2380 @entity33 @entity17101 @entity3219 @entity6656 @entity1328
OBJECTIVE: To describe the association between @entity2380 and reversible @entity1665 . DESIGN: A retrospective survey of 1) @entity1 enrolled in NIAID Mycoses Study Group (MSG) protocols involving the long-term use of @entity2380 for treatment of endemic mycoses and 2) @entity1 treated with @entity2380 outside of a protocol setting but by the MSG investigators who were MSG members. SETTING: 26 MSG sites in the United States. @entity1 : 33 @entity1 with various deep and superficial mycoses who developed @entity1665 while receiving @entity2380 . RESULTS: 11 of 26 investigators reported a total of 33 @entity1 with substantial @entity1665 related to @entity2380 therapy. Underlying mycoses included @entity17101 , @entity19406 , @entity3219 , @entity1328 , @entity6656 , and @entity33 . In separate MSG studies, 17 of 136 (12.5%) and 8 of 40 (20%) @entity1 had substantial reversible @entity1665 associated with @entity2380 therapy. Eight @entity1 who were not in the protocol had similar adverse effects. Twenty-nine of 33 @entity1 (88%) received at least 400 mg of @entity2380 daily for a mean of 7.1 months. @entity1665 developed a median of 3 months after initiation of @entity2380 therapy and involved the scalp in all @entity1 . Other sites were involved in about one third of @entity1 . Three @entity1 required wigs because of extensive hair loss. @entity1665 resolved within 6 months of discontinuation of @entity2380 therapy or reduction of the daily dose by at least 50%. CONCLUSIONS: @entity1665 appears to be a common adverse event associated with higher-dose (400 mg/d) @entity2380 given for 2 months or longer. This effect may be severe but is reversed by discontinuing @entity2380 therapy or substantially reducing the daily dose.
